Department of Dermatology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107 West Yanjiang Rd, Guangzhou, 510120, China.
Mycopathologia. 2013 Feb;175(1-2):57-67. doi: 10.1007/s11046-012-9577-0. Epub 2012 Sep 17.
Penicillium marneffei is an emerging pathogenic fungus that can cause a life-threatening systemic mycosis in immunocompromised hosts, especially in patients with AIDS. This infection is endemic in Southeast Asia. With the prevalence of AIDS in this area, the number of patients with systemic penicilliosis marneffei is found to be increasing rapidly in mainland China in recent years. We recently reviewed 668 cases of penicilliosis marneffei in mainland China from January 1984 to December 2009 in cnki, cqvip, CBMdisc and PubMed. We analyzed epidemiological and clinical features, laboratory findings, reaction to therapy and prognosis of the disease. We found that 99.4% of the cases were reported in the southern part of China; among these cases, 42.8% were from Guangxi (286 cases) and 40.6% were from Guangdong province (271 cases). Five hundred and eighty-six cases (87.7%) of penicilliosis marneffei were reported with infection by the human immunodeficiency virus, 25 cases (3.8%) with other immunocompromised diseases, and 57 cases (8.5%) without any documented underlying diseases. Fever, weight loss, anemia, lymphadenopathy, hepatosplenomegaly, respiratory signs and skin lesions were the common clinical manifestations of P. marneffei infections. The 569 cases received antifungal therapy with a mortality of 24.3% (138 cases), 99 cases who had not received antifungal therapy had a mortality of 50.6%. P. marneffei was an emerging pathogenic fungus and become a medical and public health importance in mainland China. The immunocompromised patients should pay more attention to P. marneffei infection in the endemic areas.
马尔尼菲青霉是一种新兴的致病真菌,可导致免疫功能低下宿主发生致命性系统性真菌感染,尤其是 AIDS 患者。这种感染在东南亚流行。随着该地区 AIDS 的流行,近年来在中国内地,系统性马尔尼菲青霉病患者的数量迅速增加。我们最近在 cnki、cqvip、CBMdisc 和 PubMed 上回顾了 1984 年 1 月至 2009 年 12 月中国内地 668 例马尔尼菲青霉病病例。我们分析了该病的流行病学和临床特征、实验室检查结果、治疗反应和预后。我们发现,99.4%的病例报告来自中国南方;在这些病例中,42.8%来自广西(286 例),40.6%来自广东省(271 例)。586 例(87.7%)马尔尼菲青霉病报告感染人类免疫缺陷病毒,25 例(3.8%)有其他免疫功能低下疾病,57 例(8.5%)无任何记录的潜在疾病。发热、体重减轻、贫血、淋巴结病、肝脾肿大、呼吸道症状和皮肤损害是马尔尼菲青霉感染的常见临床表现。569 例接受了抗真菌治疗,死亡率为 24.3%(138 例),99 例未接受抗真菌治疗的死亡率为 50.6%。马尔尼菲青霉是一种新兴的致病真菌,在中国内地已成为医学和公共卫生的重要问题。免疫功能低下的患者应更加注意流行地区的马尔尼菲青霉感染。